There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.
Business Insider Africa on MSN
Ozempic maker launches cheaper copy in Africa’s largest pharma market after court blocks unregistered Ozempic copies
Novo Nordisk is launching a cheaper authorised version of its blockbuster diabetes drug Ozempic in South Africa, intensifying ...
WATE 6 On Your Side on MSN
GLP-1 insurance change impacts millions of Americans: What to know, how to tell if you’re covered
Insurance coverage just changed for as many as 56 million Americans when it comes to the popular GLP-1 medications used to ...
By Nqobile Dludla JOHANNESBURG, July 17 (Reuters) - Novo Nordisk will launch a more affordable authorised copy of its Ozempic ...
GC Green Cross is moving in earnest to build high-value production infrastructure for its entry into the US subcutaneous ...
Startups are testing GLP-1 treatments for overweight cats while pet-food giants are leaning into longevity products as owners ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results